Core Laboratories Inc. (NYSE:CLB) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Larry Bruno - Chairman and Chief Executive Officer Gwen Gresham - Senior Vice President and Head, Investor Relations Chris Hill - Chief Financial Officer Conference Call Participants Stephen Gengaro - Stifel Sean Mitchell - Daniel Energy Partners Operator Good day and welcome to the Core Laboratories N. V. First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. ...

Core Laboratories Earnings Summary - Core Laboratories reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 per share, and down from $0.19 per share a year ago, representing an earnings surprise of -6.67% [1] - The company posted revenues of $123.59 million for the quarter, missing the Zacks Consensus Estimate by 0.38%, and down from $129.64 million year-over-year [2] - Over the last four quarters, Core Laboratories has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance and Outlook - Core Laboratories shares have declined approximately 28.1% since the beginning of the year, compared to a decline of -10.1% for the S&P 500 [3] - The company's earnings outlook is currently unfavorable, leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $127.62 million, and for the current fiscal year, it is $0.76 on revenues of $508.9 million [7] Industry Context - The Oil and Gas - Field Services industry, to which Core Laboratories belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a relatively strong industry performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Exhibit 99.1 FOR IMMEDIATE RELEASE CORE LAB REPORTS FIRST QUARTER 2025 RESULTS: HOUSTON (April 23, 2025) - Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported first quarter 2025 revenue of $123,600,000. Core's operating income was $4,400,000, with earnings per diluted share ("EPS") of $0.00, all in accordance with U.S. generally accepted accounting principles ("GAAP"). Operating income, ex-items, a non-GAAP financial measure, was $11,800,000, yielding operating margins of 10 ...

Core Laboratories Inc. (CLB) , an oilfield services company, operates in more than 50 countries and specializes in reservoir management and production enhancement. Its shares have risen 26.9% in the past six months, outperforming the broader oil and energy sector's  1.3% growth. The stock has also surpassed the Field Services sub-industry and competitors like TechnipFMC (FTI) , which gained 15.5%, Halliburton (HAL) and Liberty Energy (LBRT) , which fell 11.6% and 13%, respectively. 6-Month Price Performance ...

It has been about a month since the last earnings report for Core Laboratories (CLB) . Shares have lost about 16% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Core Laboratories due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Core Laboratories’ Q4 Earnings Bea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to _______________ Commission File Number 001-41695 CORE LABORATORIES INC. (Exact name of registrant as specified in its charter) | Delaware | 98- ...

Core Points - Core Laboratories Inc. (CLB) reported fourth-quarter 2024 adjusted earnings of 23 cents per share, exceeding the Zacks Consensus Estimate of 21 cents and up from 19 cents in the prior year, driven by strong performance in the Reservoir Description segment [1] - The company's operating revenues for the fourth quarter were $129.2 million, slightly missing the Zacks Consensus Estimate of $131 million, but representing a 0.9% increase from $128 million in the same quarter last year, attributed to the Reservoir Description segment [2] - CLB repurchased 264,982 shares for $4.9 million and reduced its debt leverage ratio to 1.31, down from 1.47 as of September 30, 2024, while decreasing net debt by $11.7 million [3] Segment Performance - **Reservoir Description**: Revenues increased by 2.1% to $86.8 million from $85 million year-over-year, although it fell short of the estimate of $88.2 million. Operating income rose from $12 million to $16.5 million, surpassing the estimate of $12.6 million due to increased demand for reservoir analysis [4] - **Production Enhancement**: Revenues decreased by 3.6% to $42.4 million from $44 million in the prior year, missing the estimate of $42.7 million. The segment reported an operating loss of $2.6 million, contrasting with an expected operating income of $3.6 million, primarily due to lower U.S. onshore completion activity [5] Financial Overview - Total costs and expenses for the fourth quarter were $115.1 million, a 1.3% increase from the previous year, slightly below the estimate of $115.2 million [6] - As of December 31, 2024, CLB had cash and cash equivalents of $19.2 million and long-term debt of $126.1 million, with a debt-to-capitalization ratio of 32.9%. Net cash from operating activities was $20.6 million, leading to a positive free cash flow of $16 million after capital expenditures of $4.4 million [7] - The board declared a quarterly dividend of 1 cent per share, unchanged from the previous quarter, payable on March 3 [8] Management Outlook - CLB anticipates a decline in activity in some regions during the first quarter of 2025 due to geopolitical risks and seasonal industry patterns [9] - For Q1 2025, revenues are expected to range from $121 million to $127 million, with operating income between $10.2 million and $12.8 million, and earnings per share projected between 12 cents and 16 cents [10] - The Reservoir Description segment is expected to generate revenues between $82 million and $85 million, while the Production Enhancement segment is projected to bring in revenues between $39 million and $42 million [11][12] - The company expects to maintain positive free cash flow and focus on strategic goals, including debt reduction and technology investments to meet client needs [14][15] Industry Context - Industry forecasts indicate crude oil demand growth of approximately 1.1-1.4 million barrels per day in 2025, necessitating continued investment in oil field development [16] - The company expects crude oil markets to remain volatile due to global economic uncertainties and geopolitical risks, with expanded sanctions disrupting crude oil trading [17] - CLB plans to remain engaged in long-term international projects, with stable activity expected in regions like the South Atlantic Margin and North Africa, while U.S. onshore activity may remain flat or decline slightly [18] Key Projects and Technology - In Q4 2024, CLB completed a study for a Middle Eastern National Oil Company using its Nuclear Magnetic Resonance technology, which improved the accuracy of recoverable reserves estimation [19][20] - The company utilized its STIMGUNTM propellant technology in Southeast Asia, resulting in a 55% increase in expected natural gas production from a low-permeability gas reservoir [21] - CLB also assisted a Canadian operator in confirming oil production from 87% of traced horizontal well legs using its FlowProfiler oil tracers [22]

Financial Data and Key Metrics Changes - Fourth quarter revenue decreased by just under 4% compared to Q3 2024, but full year revenue increased by 3% [11] - Operating income and earnings per share were down sequentially in Q4, but for the full year 2024, operating income was up 7% and earnings per share were up 9% compared to 2023 [11] - For the full year 2024, earnings per diluted share ex-items was $0.87, representing a year-over-year growth of 9% [17][36] Business Line Data and Key Metrics Changes - In Reservoir Description, Q4 revenue was down 2% compared to Q3 2024 but up 3% year-over-year, with operating margins at 16% [12][60] - In Production Enhancement, Q4 revenue decreased by 7% sequentially and was roughly flat for the full year 2024 versus 2023, with operating margins at 4% [13][64] - Full year service revenue was $388.2 million, up over 4% compared to 2023, while product sales were $32.7 million for Q4, down 8% sequentially and down 2% year-over-year [25][36] Market Data and Key Metrics Changes - The company experienced a higher level of international product sales in 2024, offset by a decline in US product sales due to lower onshore completion activity [14] - Geopolitical conflicts and sanctions negatively impacted demand for laboratory services tied to crude oil and derived products [12][26] - The company anticipates that US onshore activity levels will begin to improve in 2025, despite current declines [28] Company Strategy and Development Direction - Core Laboratories continues to focus on technology investments to solve client problems and capitalize on geographic opportunities [10][48] - The company aims to maximize free cash flow, return on invested capital, and return excess free cash to shareholders [18][19] - Core Lab is expanding its portfolio of innovative offerings and opened a completion diagnostics lab in the Middle East [59] Management's Comments on Operating Environment and Future Outlook - Management maintains a constructive long-term outlook on international upstream projects for 2025, despite near-term volatility in crude oil markets [48][50] - The company expects mid-single-digit growth year-over-year in demand for its services and products, particularly in international markets [50][58] - Management acknowledges that geopolitical disruptions have had an outsized impact on margins, particularly in Q1 2025 [106] Other Important Information - The company reduced its net debt by nearly $12 million in Q4, decreasing the leverage ratio to 1.31%, the lowest in eight years [15][40] - Cash flow from operating activities was $20.6 million in Q4, leading to a free cash flow of $16.2 million [43] - Capital expenditures for 2025 are expected to be elevated due to the rebuilding of the Aberdeen facility, estimated between $10 million and $12 million [44][45] Q&A Session Summary Question: Competitive dynamics and pricing environment in the US production enhancement market - Management noted that the market is crowded with competition, leading to stable pricing but not necessarily higher prices for technology [76][78] Question: R&D business internationally and pricing drivers for 2025 - Management expects a seasonal decline in Q1 but remains optimistic about mid-single-digit growth in international reservoir description operations [80][84] Question: Details on international market growth and muted areas for 2025 - Management highlighted strong project activity in the Middle East and South Atlantic margin, while noting challenges in Mexico [90][93] Question: Impact of Q1 weather on operations - Management reported significant closures due to severe weather, resulting in approximately $1 million of lost revenue [99] Question: Geopolitical disruptions and their impact on margins - Management confirmed that geopolitical disruptions have significantly affected profitability, particularly in Q1 [106]

Group 1 - Core Laboratories Inc. held its Fourth Quarter 2024 Earnings Conference Call on January 30, 2025, with key participants including the Chairman and CEO, CFO, and Head of Investor Relations [1][2][3] - The call was structured into six segments, starting with remarks on forward-looking statements, followed by a high-level review of Q4 performance [4] - The company emphasized its strategies and three financial principles aimed at building long-term shareholder value [5] Group 2 - The CFO provided a detailed financial overview and additional comments regarding shareholder value [5] - The Head of Investor Relations discussed the company's outlook and guidance for the future [6] - The CEO reviewed the two operating segments of Core Laboratories, highlighting progress and the successful introduction of new technologies [6]

Core Laboratories Earnings Summary - Core Laboratories reported quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share, but showing an increase from $0.19 per share a year ago, resulting in an earnings surprise of -4.35% [1] - The company posted revenues of $129.24 million for the quarter ended December 2024, which was 1.27% below the Zacks Consensus Estimate, but slightly above the year-ago revenues of $128.21 million [2] - Over the last four quarters, Core Laboratories has surpassed consensus EPS estimates two times and has topped consensus revenue estimates two times [2] Stock Performance and Outlook - Core Laboratories shares have increased approximately 7.1% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Core Laboratories is currently unfavorable, leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Future Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.23 on revenues of $131.62 million, and for the current fiscal year, it is $1.02 on revenues of $542.45 million [7] - The outlook for the Oil and Gas - Field Services industry, where Core Laboratories operates, is currently in the bottom 16% of Zacks industries, which may impact stock performance [8]